BridgeBio Oncology Therapeutics (BBOT) Registration filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on developing novel small-molecule therapeutics targeting RAS and PI3K pathways for cancer treatment.

• Pipeline includes three orally bioavailable small molecule inhibitors designed to address key gaps in RAS-focused therapies, with potential for combination regimens in KRAS mutant tumors.

• Fast Track designations from the FDA for lead candidates BBO-8520 (KRAS G12C-mutated NSCLC) and BBO-11818 (KRAS-mutant PDAC).

• Originated as a subsidiary of BridgeBio Pharma, completed a business combination with Helix Acquisition Corp. II in August 2025, and is now listed on Nasdaq under the ticker BBOT.

Financial performance and metrics

• As of June 30, 2026, net tangible book value was $323.1 million, or $4.03 per share, with 80,115,002 shares outstanding.

• After a $200 million offering at $8.80 per share, pro forma net tangible book value would be $516.6 million, or $5.02 per share, resulting in immediate dilution of $3.78 per share to new investors.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for research and clinical development of current or additional product candidates, working capital, capital expenditures, and general corporate purposes.

• Management retains broad discretion over allocation; proceeds may be temporarily invested in high-quality, investment-grade instruments or held as cash.